Intestinal Parasite Profile in the Stool of HIV Positive Patients in relation to Immune Status and Comparison of Various Diagnostic Techniques with Special Reference to Cryptosporidium at a Tertiary Care Hospital in South India
Table 1
Results.
Patient characteristics
All patients ()
Patients with intestinal parasites ()
Patients without intestinal parasites ()
value
Gender male, (%)
136 (68%)
17 (94.4%)
119 (65.4%)
0.012
WHO staging of HIV, (%)
0.076
Stage 1
11 (5.5%)
0 (0%)
11 (6%)
Stage 2
34 (17%)
2 (11%)
32 (17.6%)
Stage 3
145 (72.5%)
13 (72.2%)
132 (72.5%)
Stage 4
10 (5%)
3 (16.7%)
7 (3%)
Diarrhoea, (%)
91 (45.5%)
15 (83.3%)
76 (41.8%)
0.001
Immune status, (%)
0.000
No immunosuppression (CD4 > 500 cells/µL)
76 (38%)
1 (5.6%)
75 (41.2%)
Mild immunosuppression (CD4 350–499 cells/µL)
40 (20%)
3 (16.7%)
37 (20.3%)
Advanced immunosuppression (CD4 200–349 cells/µL)
34 (17%)
2 (11.1%)
32 (17.6%)
Severe immunosuppression (CD4 < 200 cells/µL)
50 (25%)
12 (66.7%)
38 (20.9%)
HAART, (%)
147 (73.5%)
13 (72.2%)
134 (73.6%)
0.898
Cotrimoxazole prophylaxis, (%)
57 (28.5%)
5 (27.8%)
52 (28.6%)
0.943
Drinking water, (%)
0.004
Boiled water
87 (43.5%)
2 (11.1%)
85 (46.7%)
Tap water
113 (56.5%)
16 (88.9%)
97 (53.3%)
WHO, World Health Organisation; HAART, highly active antiretroviral therapy.
